Share this page!

Eric Topol Profile picture
Twitter logo
3 Nov, 4 tweets, 2 min read
The next chapter of anti-Covid is about to start with pills that inactivate the virus, irrespective of variants. First will be Molnupiravir in a matter of weeks, then this one.
Helping to get us onto an exit ramp. science.org/doi/10.1126/sc…
@ScienceMagazine
These will add an important new layer of defense early after symptom onset w/ test positive confirmation and also, as clinical trials get completed, for known exposure
Success of the Covid pill era depends on rapid tests that are widely available, free or very inexpensive, and accurate. While the pills are coming soon, the US is still woefully unprepared for their roll out.
The trade name for the 1st pill is Lagevrio and it's already moving forward

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Eric Topol

Eric Topol Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @EricTopol

Eric Topol Profile picture
30 Oct
There's currently one continental outlier: Europe
@OurWorldInData
The top 10 countries for covid cases/capital globally are all in Eastern Europe
While there has been an increase in cases in several Western European countries, it is small (per capita) relative to the previous group
Read 4 tweets
Eric Topol Profile picture
28 Oct
A new, rigorous and important study of Covid transmission—with or without prior vaccination—in 621 people with mild infections
Just published @TheLancetInfDis
thelancet.com/lancet/article…
Vaccination reduced spread, but it still occurred in household contacts (unvaxx 38%, vaxx 25%)
Viral load was assessed from 8145 respiratory tract samples for up to 20 days, irrespective of symptoms

The peak load (Delta variant) was similar for unvaccinated vs vaccinated cases, but faster clearance in the latter

All breakthrough cases were mild
From the accompanying editorial
thelancet.com/pb-assets/Lanc…
“This study unfortunately also highlights that the vaccine effect on reducing transmission is minimal in the context of Delta variant circulation”
Read 5 tweets
Eric Topol Profile picture
27 Oct
This is what a real breakthrough infection report should look like. Thanks Oregon oregon.gov/oha/covid19/Do…
People < age 60 are not "immune" from hospitalizations and deaths
J&J>Pfizer>Moderna
Currently ~1/4 of cases
We still do not have this for the US, let alone most states
In contrast, the US has only posted such data once, now 2 months outdated, and represent only ~30% of the country
covid.cdc.gov/covid-data-tra… @CDCgov
If the US ever produced and published an up-to-date, informative report, it would be a real breakthrough
Hello @HHSgov @WHCOVIDResponse @CDCgov
Read 5 tweets
Eric Topol Profile picture
27 Oct
2 new @NatureMedicine papers
First from half of US public school data
"Schools can open for in-person learning during the pandemic with minimal contribution to sustained community incidence of infections, provided other public safety measures are adopted."
nature.com/articles/s4159… Image
2nd from Japan
"We do not find any evidence that school closures in Japan reduced the spread of COVID-19."
nature.com/articles/s4159… Image
As US schools opened, kids hospital admissions "plunged".
Counter to many predictions
bloomberg.com/news/articles/… Image
Read 4 tweets
Eric Topol Profile picture
26 Oct
Young children, age 5/6-11, and vaccination dose of mRNA
Pfizer used 10 μg in their trial of 2,270 children w/ 90.7% efficacy vs symptomatic infections
Moderna used 50 μg in their trial of 4,753 children
Wondering about this 5X mRNA dose; both trials small for v rare side effects
Another issue:
We have learned that vaccine dose spacing 8-12 weeks induces a better immune response than short (3-4 week spacing). Why hasn't this been incorporated in the new trials and roll out?
The event curve for symptomatic infections in the age 5-11 Pfizer trial presented at FDA today (2 doses given, 3 weeks apart)
fda.gov/media/153513/d…
Read 4 tweets
Eric Topol Profile picture
21 Oct
The 1st randomized trial of a booster (3rd) shot in 10,000 people, placebo-controlled, shows 95.6% efficacy, with 5 cases (Pfizer vaccine) vs 109 in placebo group, Delta variant, broad benefit across age groups ft.com/content/d4e58d…
Until now there were only vaccine effectiveness reports without randomization, without a placebo control group, and multiple potential confounding factors. That’s what makes this trial report significant proof of benefit of booster shots, at least for this vaccine regimen.
Current booster recommendations. They are going to need to be revised.
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @EricTopol has new unrolls!

Check out other threads from @EricTopol!

Read all threads by @EricTopol

:(